KONEXElectrical Equipment212310

Organ Eco Tech

₩635 0.00%2026-11-18 close
Market Cap
₩7.5B
Turnover
₩0
Volume
0 shares
Shares out.
11.8M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Trading Halt and a Listing in the Balance

Despite its electrical-equipment classification, Organ Eco Tech is a spinal-implant-centered medical device maker, and the trading halt in place since April 8, 2025 and the delisting review are the central issues.

  1. 1

    Organ Eco Tech is a medical device maker listed on KONEX on July 26, 2016, so its actual business differs from the electrical-equipment sector label.

  2. 2

    For fiscal 2024, revenue was KRW 369 million and net loss was KRW 92 million, with total assets of KRW 4.692 billion against total liabilities of KRW 5.320 billion, a state of full capital impairment.

  3. 3

    The trading suspension period has run since April 8, 2025, and KRW 635 is the last close before the suspension.

  4. 4

    A March 2025 rights offering (debt-to-equity conversion) changed the largest shareholder group from T-Life and eight others to HM Networks and eight others.

  5. 5

    The CEO's term expired on October 1, 2026 with no successor named, and an extraordinary shareholders' meeting on November 17, 2026 will take up director appointments.

02

Business structure

Organ Eco Tech was established on November 10, 2006, and it is a medical device maker listed on KONEX on July 26, 2016. Its main products are spinal implants and related items, centered on spinal implants and surgical instruments used in orthopedics and neurosurgery. The English DART company profile lists its industry as manufacture of dental prosthesis.

The company's website describes it as a bio and polymer materials specialist and an export-oriented medical device company. The business highlights on the website list bio materials, polymer business and medical cosmetics. A revenue breakdown by product line could not be verified from disclosures, so none is given here.

A business transfer decision was disclosed on January 10, 2025, and cancellation of the transfer agreement was disclosed on April 11, 2025. This means one restructuring attempt did not go through.

Electrical-equipment peers such as LS Electric, HD Hyundai Electric and Hyosung Heavy Industries make power equipment and do not overlap with its business. Direct comparison with them therefore carries little meaning.

03

Recent trends

For fiscal 2024, revenue was KRW 369 million and net loss was KRW 92 million, and the company was in full capital impairment. On March 27, 2025, a rights offering moved the largest shareholder group from T-Life and eight others (4,593,197 shares, 43.33%) to HM Networks and eight others. The stated purpose of the stake acquisition was a debt-to-equity conversion.

On April 8, 2025, share trading was suspended because the auditor's delayed report left the annual report unfiled. The April 17, 2025 audit report disclosure confirmed a disclaimer of opinion citing a scope limitation and uncertainty over going-concern ability.

The company filed an appeal on May 12, 2025 and was granted an improvement period. Unfaithful-disclosure designations followed on May 27, 2025 (reversal of disclosures) and June 19, 2025 (failure to disclose), the first including a prior notice.

On March 23, 2026, the company disclosed a delay in the audit report because the auditor had not obtained sufficient audit evidence amid late submission of accounting materials.

The annual and audit reports were filed on March 31, 2026, followed by a notice on April 10 about the delisting decision after the improvement period, an appeal filing on April 21, a notice on May 4 about submission of the improvement-plan implementation report, and a June 2 notice that the Listing Disclosure Committee would resume deliberation.

Press coverage reported that a disclaimer of opinion due to a scope limitation created a delisting ground for the latest fiscal year. A final delisting decision could not be confirmed. The quoted price of KRW 635 is the last close before the suspension, and turnover is zero.

04

Outlook

The largest variable ahead is the exchange's decision on delisting, and no final outcome could be confirmed as of this research. The suspension remains in place while deliberations continue. The suspension tied to the fiscal 2024 audit opinion lasts until the delisting decision date after the improvement period ends.

Whether the management vacuum is resolved is also worth watching. CEO Park Jung-min's term expired and no successor has been decided. The November 17, 2026 extraordinary shareholders' meeting will take up the appointment of four inside directors and two independent directors, with a record date of October 23, 2026.

Several medical device companies have had trading halted over audit-opinion problems. Press reports noted a rising number of medical device firms whose trading was suspended for audit-opinion refusals or listing-eligibility review grounds.

Room for improvement in business metrics such as operating margin or utilization can only be judged once finalized financial statements and disclosures are confirmed. Price formation is uncertain if trading resumes. If delisting is confirmed, investors' routes for trading on the market change fundamentally. Disclosures and exchange notices after the November extraordinary meeting should continue to be checked.

05

Bull factors

Attempts to repair the capital structure

The March 2025 rights offering was structured as a debt-to-equity conversion. Converting debt to equity is a step that lowers financial burden. One reading is that a new largest shareholder created conditions to pursue a normalization plan. The actual extent of financial improvement must be checked against finalized financial statements.

The review process is still under way

The company was granted an improvement period after its appeal in May 2025. In 2026, the appeal filing, the improvement-plan implementation report and the decision to resume committee deliberation followed.

The fact that deliberation has not concluded and the explanation process continues means a path to keeping the listing remains open. The final judgment rests with the exchange.

Expansion toward materials businesses

The company website puts bio materials, polymer business and medical cosmetics in its business highlights. The direction is to broaden the business from a single spinal-implant line into materials.

The company's description of itself as an export-oriented medical device firm also signals intent toward overseas sales channels. Whether these businesses have turned into actual revenue could not be confirmed from disclosures.

06

Bear factors

Audit disclaimer and delisting grounds

In April 2025 the auditor issued a disclaimer of opinion citing a scope limitation and going-concern uncertainty. According to press reports, a disclaimer due to a scope limitation again created a delisting ground for the latest fiscal year, and whether the listing survives is uncertain.

In March 2026 the company also explained that audit evidence was insufficient because of late submission of audit materials. Concerns about accounting transparency and internal controls have recurred.

Minimal revenue and capital impairment

Revenue for 2024 was only KRW 369 million, with a net loss of KRW 92 million and full capital impairment. Total liabilities exceed total assets, leaving shareholders' equity negative. The small revenue base means the earnings foundation to cover fixed costs is thin. The 2025 results could not be verified from a reliable disclosure source, so no figures are given.

Disclosure credibility and a management vacuum

Unfaithful-disclosure designations were announced on May 27, 2025 (reversal) and June 19, 2025 (failure to disclose). The business transfer decision led to a cancellation in April 2025, and convertible bond issuance and litigation-related disclosures recurred.

In addition, the CEO's term has expired with no successor decided. Instability in the decision-making structure can slow normalization.

07

Risk factors

Regulatory

Whether the company is delisted depends on the exchange's deliberation. The suspension tied to the fiscal 2024 audit opinion stays in place until the delisting decision date after the improvement period. If delisting is decided, the trading route on the KONEX market disappears. The timetable and result can be confirmed only through exchange disclosures.

Liquidity

The quoted price of KRW 635 is the last close before the suspension and turnover is zero. If the halt is prolonged or delisting proceedings begin in earnest, usual exit routes such as on-market sales or block deals can be effectively blocked.

There is no basis to assume the pre-suspension price holds if trading resumes. The KRW 7.5 billion market capitalization is also derived from that same price.

Financial and governance

The company was in full capital impairment as of the 2024 year-end, and any recovery since must be verified against finalized financial statements. Convertible bond issuance decisions and conversion-right exercise disclosures recurred from 2025 onward, which raises the possibility of dilution from a larger share count.

The CEO position is also vacant. The director appointments at the November 17, 2026 extraordinary meeting would be a first step toward governance stability.

08

Overall view

Despite its electrical-equipment classification, Organ Eco Tech makes spinal implants and surgical instruments as a medical device company. For fiscal 2024, revenue was only KRW 369 million and the company was in full capital impairment, and trading has been suspended since April 8, 2025.

The largest-shareholder change, the debt-to-equity conversion, the appeal and the improvement-plan filings show that steps to maintain the listing are continuing, which can be read positively as fact.

On the other hand, repeated audit disclaimers, unfaithful-disclosure designations, the cancelled business transfer and the vacant CEO post are burdens.

The KRW 635 quote and KRW 7.5 billion market capitalization rest on the last price before the suspension, so they should not be equated with a current market assessment.

The outcome of the November 17, 2026 extraordinary meeting and the exchange's delisting decision are the next checkpoints, and this report is for information only, leaving judgment to the reader.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 11 more articles and sources
  1. m.news.nate.com
  2. newstopkorea.com
  3. organecotech.kr
  4. m.irgo.co.kr
  5. digitaltoday.co.kr
  6. digitaltoday.co.kr
  7. m.news.nate.com
  8. news.nate.com
  9. m.news.nate.com
  10. englishdart.fss.or.kr
  11. dailymedi.com

Report written 2026-10-27 · Data as of 2026-10-26

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis